

# Cardiomyopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C032B320B428EN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: C032B320B428EN

## Abstracts

The 7 major cardiomyopathy markets are expected to exhibit a CAGR of 6.07% during 2024-2034.

The cardiomyopathy market has been comprehensively analyzed in IMARC's new report titled "Cardiomyopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cardiomyopathy refers to a group of diseases that affect the cardiac muscle, making it harder for the heart to pump blood effectively. It is a progressive and chronic disorder that can lead to arrhythmias, heart failure, and other health complications, like stroke and sudden death. Some common symptoms of the ailment may include fatigue, chest pain or discomfort, a sensation of rapid, fluttering, or pounding heartbeat, shortness of breath, dizziness, swelling of the legs, ankles, and feet, weight gain, lightheadedness, wheezing, loss of appetite, bloating or fluid in the abdomen, persistent coughing, etc. The diagnosis of this illness typically requires a combination of medical history evaluation, physical examination, and characteristic findings. An electrocardiogram is also recommended to record the electrical activity of the heart and determine abnormal rhythms or patterns that may indicate cardiomyopathy. Furthermore, blood tests are utilized to measure levels of certain enzymes, proteins, and genetic markers associated with the condition. A healthcare provider may perform magnetic resonance imaging to obtain detailed pictures of the heart that help to determine the type and extent of the disease.

The increasing cases of genetic mutations or variations, which can affect the function and anatomy of the cardiac muscle, are primarily driving the cardiomyopathy market. In addition to this, the rising prevalence of various risk factors, such as high blood

pressure, heart valve problems, metabolic disorders, infections, alcohol abuse, exposure to toxins, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, including beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, diuretics, etc., to manage disease symptoms and enhance the quality of life is further bolstering the market growth. Apart from this, the inflating application of implantable cardioverter-defibrillator devices, which help to continuously monitor the heart rate and automatically deliver an electric shock to restore normal rhythm in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of septal ablation procedures for the treatment of the disease, owing to their numerous advantages, such as lower mortality rates, shorter hospital stays, and improved blood flow, is expected to drive the cardiomyopathy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the cardiomyopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cardiomyopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cardiomyopathy market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the cardiomyopathy market  
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the cardiomyopathy market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cardiomyopathy marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the cardiomyopathy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the cardiomyopathy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the cardiomyopathy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cardiomyopathy across the seven major markets?

What is the number of prevalent cases (2018-2034) of cardiomyopathy by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of cardiomyopathy by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with cardiomyopathy across the seven major markets?

What is the size of the cardiomyopathy patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of cardiomyopathy?

What will be the growth rate of patients across the seven major markets?

### Cardiomyopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for cardiomyopathy drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the cardiomyopathy market?

What are the key regulatory events related to the cardiomyopathy market?

What is the structure of clinical trial landscape by status related to the cardiomyopathy market?

What is the structure of clinical trial landscape by phase related to the cardiomyopathy market?

What is the structure of clinical trial landscape by route of administration related to the cardiomyopathy market?

## Contents

?1 Preface

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 CARDIOMYOPATHY - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 CARDIOMYOPATHY - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 CARDIOMYOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 CARDIOMYOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 CARDIOMYOPATHY - UNMET NEEDS**

## **10 CARDIOMYOPATHY - KEY ENDPOINTS OF TREATMENT**

## **11 CARDIOMYOPATHY - MARKETED PRODUCTS**

- 11.1 List of Cardiomyopathy Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Camzyos (Mavacamten) - Bristol Myers Squibb/MyoKardia
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Tafamidis (Tafamidis meglumine) - Pfizer
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 CARDIOMYOPATHY - PIPELINE DRUGS**

### 12.1 List of Cardiomyopathy Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Aficamten - Cytokinetics
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status
- 12.1.2 MYK-224 - Bristol-Myers Squibb
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. CARDIOMYOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. CARDIOMYOPATHY – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 CARDIOMYOPATHY - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets

- 15.2.1 Cardiomyopathy - Market Size
  - 15.2.1.1 Market Size (2018-2023)
  - 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Cardiomyopathy - Market Size by Therapies
  - 15.2.2.1 Market Size by Therapies (2018-2023)
  - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Cardiomyopathy - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Cardiomyopathy - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Cardiomyopathy - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Cardiomyopathy - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Cardiomyopathy - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Cardiomyopathy - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Cardiomyopathy - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Cardiomyopathy - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Cardiomyopathy - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Cardiomyopathy - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Cardiomyopathy - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Cardiomyopathy - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy

- 15.7.1 Cardiomyopathy - Market Size
  - 15.7.1.1 Market Size (2018-2023)
  - 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Cardiomyopathy - Market Size by Therapies
  - 15.7.2.1 Market Size by Therapies (2018-2023)
  - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Cardiomyopathy - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Cardiomyopathy - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Cardiomyopathy - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Cardiomyopathy - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Cardiomyopathy - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Cardiomyopathy - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Cardiomyopathy - Access and Reimbursement Overview

## **16 CARDIOMYOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 CARDIOMYOPATHY MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 CARDIOMYOPATHY MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Cardiomyopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C032B320B428EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C032B320B428EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

